Immunomedics Announces Combo of 90Y-Epratuzumab-Veltuzumab is Active in ... Benzinga 1 Moreover, given that the anti-CD20 veltuzumab also compared well to published results with rituximab,^2,3 the Company is conducting a Phase I/II study to evaluate the potential of ^90Y-epratuzumab combined with veltuzumab in patients with aggressive ... Immunomedics (IMMU) Issues Encouraging Update for Epratuzumab w/ 90Y on ... |
